Ocuphire Pharma Inc R3X1-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 7:55 PM CET
7.55quote price arrow down-0.10 (-1.31%)
52 week range
3.18 - 17.68

...

Loading . . .

KEY STATS

  • Open7.75
  • Day High7.90
  • Day Low7.50
  • Prev Close7.65
  • 52 Week High17.68
  • 52 Week High Date06/18/20
  • 52 Week Low3.18
  • 52 Week Low Date11/10/20
  • Market Cap10.49M
  • Shares Out1.12M
  • 10 Day Average Volume443.82
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-5.15

RATIOS/PROFITABILITY

  • EPS (TTM)-5.35
  • P/E (TTM)-1.41
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Ocuphire Pharma Inc News

There is no recent news for this security.

Latest R3X1-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. The Company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic...
Cam Gallagher
Chairman
Mina Sooch
President
Amy Rabourn
Chief Accounting Officer
Address
37000 Grand River Ave., Suite 120
Farmington Hills, MI
48335
United States